Repurposing the Kinase Inhibitor Mavelertinib for Giardiasis Therapy

A phenotypic screen of the ReFRAME compound library was performed to identify cell-active inhibitors that could be developed as therapeutics for giardiasis. A primary screen against Giardia lamblia GS clone H7 identified 85 cell-active compounds at a hit rate of 0.72%. A cytotoxicity counterscreen a...

Descripción completa

Detalles Bibliográficos
Autores principales: Michaels, Samantha A., Hulverson, Matthew A., Whitman, Grant R., Tran, Linh T., Choi, Ryan, Fan, Erkang, McNamara, Case W., Love, Melissa S., Ojo, Kayode K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2022
Materias:
Experimental Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295539/
https://www.ncbi.nlm.nih.gov/pubmed/35703552
http://dx.doi.org/10.1128/aac.00017-22

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9295539/
https://www.ncbi.nlm.nih.gov/pubmed/35703552
http://dx.doi.org/10.1128/aac.00017-22

Ejemplares similares